Arie Zask

Arie Zask

Auto-generated profile, based on publicly available information

Arie Zask

Department of Biological Sciences and Department of Chemistry, Columbia University, New York, New York

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2013 in Chirality
Verified
Journal Article
Closed access
AZArie Zask
Arie Zask
JMJohn Murphy
John Murphy
GEGeorge A. Ellestad
George A. Ellestad

24 January 2013 in Journal of Natural Products
Verified
Journal Article
Closed access
DJDharati Joshi
Dharati Joshi
JFJames Field
James Field
JMJohn Murphy
John Murphy
MAMohammed Abdelrahim
Mohammed Abdelrahim
HSHeike Schönherr
Heike Schönherr
AZArie Zask
Arie Zask

15 November 2017 in Chirality
Verified
Journal Article
Closed access
PDF file
AZArie Zask
Arie Zask
GEGeorge Ellestad
George Ellestad

1 November 2004 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AYAyako Yamashita
Ayako Yamashita
ENEmily B. Norton
Emily B. Norton
JKJoshua A. Kaplan
Joshua A. Kaplan
CNChuan Niu
Chuan Niu
FLFrank Loganzo
Frank Loganzo
SASemiramis Ayral-Kaloustian
Semiramis Ayral-Kaloustian

19 August 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
CRClara Reglero
Clara Reglero
CDChelsea L. Dieck
Chelsea L. Dieck
AZArie Zask
Arie Zask
FFFarhad Forouhar
Farhad Forouhar
ALAnouchka P. Laurent
Anouchka P. Laurent
AFAdolfo A. Ferrando
Adolfo A. Ferrando
Low-intensity maintenance therapy with 6-mercaptopurine (6-MP) limits the occurrence of acute lymphoblastic leukemia (ALL) relapse and is central to the success of multiagent chemotherapy protocols. Activating mutations in the 5′-nucleotidase cytosolic II (NT5C2) gene drive resistance to 6-MP in over 35% of early relapse ALL cases. Here we identify CRCD2 as a first-in-class small-molecule NT5C2 nucleotidase inhibitor broadly active against leukemias bearing highly prevalent relapse-associated mutant forms of NT5C2 in vitro and in vivo. Importantly, CRCD2 treatment also enhanced the cytotoxic activity of 6-MP in NT5C2 wild-type leukemias, leading to the identification of NT5C2 Ser502 phosphorylation as a novel NT5C2-mediated mechanism of 6-MP resistance in this disease. These results uncover an unanticipated role of nongenetic NT5C2 activation as a driver of 6-MP resistance in ALL and demonstrate the potential of NT5C2 inhibitor therapy for enhancing the efficacy of thiopurine maintenance therapy and overcoming resistance at relapse. Significance: Relapse-associated NT5C2 mutations directly contribute to relapse in ALL by driving resistance to chemotherapy with 6-MP. Pharmacologic inhibition of NT5C2 with CRCD2, a first-in-class nucleotidase inhibitor, enhances the cytotoxic effects of 6-MP and effectively reverses thiopurine resistance mediated by genetic and nongenetic mechanisms of NT5C2 activation in ALL. This article is highlighted in the In This Issue feature, p. 2483

29 August 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSamuel J. Resnick
Samuel J. Resnick
SISho Iketani
Sho Iketani
SHSeo Jung Hong
Seo Jung Hong
AZArie Zask
Arie Zask
HLHengrui Liu
Hengrui Liu
ACAlejandro Chavez
Alejandro Chavez
We describe a mammalian cell-based assay capable of identifying coronavirus 3CL protease (3CLpro) inhibitors without requiring the use of live virus. By enabling the facile testing of compounds across a range of coronavirus 3CLpro enzymes, including the one from SARS-CoV-2, we are able to quickly identify compounds with broad or narrow spectra of activity. We further demonstrate the utility of our approach by performing a curated compound screen along with structure-activity profiling of a series of small molecules to identify compounds with antiviral activity. Throughout these studies, we observed concordance between data emerging from this assay and from live virus assays. By democratizing the testing of 3CL inhibitors to enable screening in the majority of laboratories rather than the few with extensive biosafety infrastructure, we hope to expedite the search for coronavirus 3CL protease inhibitors, to address the current epidemic and future ones that will inevitably arise.